reviral company logo

ReViral – Innovative therapies for viral diseases

ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.

The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion which will enter clinical trials in H2/2016.


Upcoming Events

28 September - 1 October 2016
RSV 16: 10th International RSV Symposium

Patagonia, Argentina 

7-9 November 2016
BIO Europe Autumn meeting
Cologne, Germany

 

Latest News
Jul 8, 2016
Qualified PhD or experienced graduate level virologist required
ReViral Ltd is an antiviral drug discovery and development company, focused on the treatment...
Jun 17, 2016
New laboratory facilities for ReViral
Refurbishment work is now completed at the North East Technology Park (NETPark) in Sedgefield...
Terms & Conditions
Privacy Policy
© Copyright ReViral 2016